Antitope, Baylor Partner for Cell-Line Development of Cancer Vaccine
Antitope Limited, an Abzena company, will develop a manufacturing cell line for the Baylor Institute for Immunology Research (BIIR), a center for translational immunology research, using its Composite CHO technology. BIIR is developing a range of therapeutic vaccines for the treatment of cancer and other diseases, and Antitope will develop a cell line for the production of BIIR's dendritic-cell-targeting vaccine for the treatment of head and neck and cervical cancer. Antitope has developed the Composite CHO technology for generating cell lines producing proteins and antibodies ready for cGMP manufacture.
Antitope is a wholly owned subsidiary of Abzena Limited, a group focused on providing proprietary technologies and value-added services to enable the development of better biopharmaceuticals. Abzena comprises two wholly owned subsidiary businesses, PolyTherics and Antitope Antitope focuses on immunogenicity assessment, protein engineering to create humanized antibodies and deimmunized therapeutic proteins, and cell line development for manufacture.PolyTherics specializes in proprietary site-specific conjugation technologies for antibody drug conjugate development and solutions for optimization of the therapeutic properties.
Source: Antitope